Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
31283407
DOI
10.1200/jco.19.00261
Knihovny.cz E-zdroje
- MeSH
- akutní lymfatická leukemie farmakoterapie genetika MeSH
- cyklofosfamid aplikace a dávkování MeSH
- cytarabin aplikace a dávkování MeSH
- daunomycin aplikace a dávkování MeSH
- etoposid aplikace a dávkování MeSH
- genová přestavba MeSH
- histonlysin-N-methyltransferasa genetika MeSH
- kojenec MeSH
- lidé MeSH
- merkaptopurin aplikace a dávkování MeSH
- míra přežití MeSH
- mitoxantron aplikace a dávkování MeSH
- novorozenec MeSH
- přežití po terapii bez příznaků nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- protoonkogenní protein MLL genetika MeSH
- výsledek terapie MeSH
- zárodečné mutace MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- cyklofosfamid MeSH
- cytarabin MeSH
- daunomycin MeSH
- etoposid MeSH
- histonlysin-N-methyltransferasa MeSH
- KMT2A protein, human MeSH Prohlížeč
- merkaptopurin MeSH
- mitoxantron MeSH
- protoonkogenní protein MLL MeSH
PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national and international study groups, tested whether myeloid-style consolidation chemotherapy is superior to lymphoid style, the role of stem-cell transplantation (SCT), and which factors had independent prognostic value. MATERIALS AND METHODS: Three risk groups were defined: low risk (LR): KMT2A germline; high risk (HR): KMT2A-rearranged and older than 6 months with WBC count 300 × 109/L or more or a poor prednisone response; and medium risk (MR): all other KMT2A-rearranged cases. Patients in the MR and HR groups were randomly assigned to receive the lymphoid course low-dose cytosine arabinoside [araC], 6-mercaptopurine, cyclophosphamide (IB) or experimental myeloid courses, namely araC, daunorubicin, etoposide (ADE) and mitoxantrone, araC, etoposide (MAE). RESULTS: A total of 651 infants were included, with 6-year event-free survival (EFS) and overall survival of 46.1% (SE, 2.1) and 58.2% (SE, 2.0). In West European/North American groups, 6-year EFS and overall survival were 49.4% (SE, 2.5) and 62.1% (SE, 2.4), which were 10% to 12% higher than in other countries. The 6-year probability of disease-free survival was comparable for the randomized arms (ADE+MAE 39.3% [SE 4.0; n = 169] v IB 36.8% [SE, 3.9; n = 161]; log-rank P = .47). The 6-year EFS rate of patients in the HR group was 20.9% (SE, 3.4) with the intention to undergo SCT; only 46% of them received SCT, because many had early events. KMT2A rearrangement was the strongest prognostic factor for EFS, followed by age, WBC count, and prednisone response. CONCLUSION: Early intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant ALL compared with the lymphoid-type course IB. Outcome for infant ALL in Interfant-06 did not improve compared with that in Interfant-99.
Australian and New Zealand Children's Haematology Oncology Group Perth Australia
Berlin Frankfurt Münster Group Germany Kiel Germany
Children Cancer Research Institute Vienna Austria
Chilean National Pediatric Oncology Group Santiago Chile
Czech Working Group for Pediatric Hematology Prague Czech Republic
Dana Farber Cancer Institute Boston MA
Dutch Childhood Oncology Group Utrecht the Netherlands
European Organisation for Research and Treatment of Cancer Children Leukemia Group Brussels Belgium
French Acute Lymphoblastic Leukemia Study Group Paris France
German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia Hamburg Germany
Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital Rome Italy
Polish Pediatric Leukemia Lymphoma Study Group Zabrze Medical University of Silesia Katowice Poland
Princess Maxima Center for Pediatric Oncology Utrecht the Netherlands
Rigshospitalet University of Copenhagen Copenhagen Denmark
Seattle Children's Hospital and Research Institute Seattle WA
St Anna Children's Hospital Medical University of Vienna Vienna Austria
St Jude Children's Research Hospital Memphis TN
United Kingdom Children Cancer Study Group London United Kingdom
University of Milano Bicocca Monza Italy
University of Pavia Pavia Italy
University of Western Australia Perth Western Australia Australia
Citace poskytuje Crossref.org
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement